TY - JOUR
T1 - CpH methylome analysis in human cortical neurons identifies novel gene pathways and drug targets for opioid use disorder
AU - Traumatic Stress Brain Research Group
AU - Nagamatsu, Sheila T.
AU - Rompala, Gregory
AU - Hurd, Yasmin L.
AU - Núñez-Rios, Diana L.
AU - Montalvo-Ortiz, Janitza L.
AU - Alvarez, Victor E.
AU - Benedek, David
AU - Che, Alicia
AU - Cruz, Dianne A.
AU - Davis, David A.
AU - Girgenti, Matthew J.
AU - Hoffman, Ellen
AU - Holtzheimer, Paul E.
AU - Huber, Bertrand R.
AU - Kaye, Alfred
AU - Krystal, John H.
AU - Labadorf, Adam T.
AU - Keane, Terence M.
AU - Logue, Mark W.
AU - McKee, Ann
AU - Marx, Brian
AU - Mash, Deborah
AU - Miller, Mark W.
AU - Noller, Crystal
AU - Scott, William K.
AU - Schnurr, Paula
AU - Stein, Thor
AU - Ursano, Robert
AU - Williamson, Douglas E.
AU - Wolf, Erika J.
AU - Young, Keith A.
N1 - Funding Information:
This study was supported by the U.S. Department of Veterans Affairs via 1IK2CX002095-01A1 (JM-O) and NIDA R21DA050160 (JM-O).
Publisher Copyright:
Copyright © 2023 Nagamatsu, Rompala, Hurd, Núñez-Rios, Montalvo-Ortiz and Traumatic Stress Brain Research Group.
PY - 2023/1/19
Y1 - 2023/1/19
N2 - Introduction: DNA methylation (DNAm), an epigenetic mechanism, has been associated with opioid use disorder (OUD) in preclinical and human studies. However, most of the studies have focused on DNAm at CpG sites. DNAm at non-CpG sites (mCpHs, where H indicates A, T, or C) has been recently shown to have a role in gene regulation and to be highly abundant in neurons. However, its role in OUD is unknown. This work aims to evaluate mCpHs in the human postmortem orbital frontal cortex (OFC) in the context of OUD. Methods: A total of 38 Postmortem OFC samples were obtained from the VA Brain Bank (OUD = 12; Control = 26). mCpHs were assessed using reduced representation oxidative bisulfite sequencing in neuronal nuclei. Differential analysis was performed using the “methylkit” R package. Age, ancestry, postmortem interval, PTSD, and smoking status were included as covariates. Significant mCpHs were set at q-value < 0.05. Gene Ontology (GO) and KEGG enrichment analyses were performed for the annotated genes of all differential mCpH loci using String, ShinyGO, and amiGO software. Further, all annotated genes were analyzed using the Drug gene interaction database (DGIdb). Results: A total of 2,352 differentially methylated genome-wide significant mCpHs were identified in OUD, mapping to 2,081 genes. GO analysis of genes with differential mCpH loci showed enrichment for nervous system development (p-value = 2.32E-19). KEGG enrichment analysis identified axon guidance and glutamatergic synapse (FDR 9E-4–2.1E-2). Drug interaction analysis found 3,420 interactions between the annotated genes and drugs, identifying interactions with 15 opioid-related drugs, including lofexidine and tizanidine, both previously used for the treatment of OUD-related symptoms. Conclusion: Our findings suggest a role of mCpHs for OUD in cortical neurons and reveal important biological pathways and drug targets associated with the disorder.
AB - Introduction: DNA methylation (DNAm), an epigenetic mechanism, has been associated with opioid use disorder (OUD) in preclinical and human studies. However, most of the studies have focused on DNAm at CpG sites. DNAm at non-CpG sites (mCpHs, where H indicates A, T, or C) has been recently shown to have a role in gene regulation and to be highly abundant in neurons. However, its role in OUD is unknown. This work aims to evaluate mCpHs in the human postmortem orbital frontal cortex (OFC) in the context of OUD. Methods: A total of 38 Postmortem OFC samples were obtained from the VA Brain Bank (OUD = 12; Control = 26). mCpHs were assessed using reduced representation oxidative bisulfite sequencing in neuronal nuclei. Differential analysis was performed using the “methylkit” R package. Age, ancestry, postmortem interval, PTSD, and smoking status were included as covariates. Significant mCpHs were set at q-value < 0.05. Gene Ontology (GO) and KEGG enrichment analyses were performed for the annotated genes of all differential mCpH loci using String, ShinyGO, and amiGO software. Further, all annotated genes were analyzed using the Drug gene interaction database (DGIdb). Results: A total of 2,352 differentially methylated genome-wide significant mCpHs were identified in OUD, mapping to 2,081 genes. GO analysis of genes with differential mCpH loci showed enrichment for nervous system development (p-value = 2.32E-19). KEGG enrichment analysis identified axon guidance and glutamatergic synapse (FDR 9E-4–2.1E-2). Drug interaction analysis found 3,420 interactions between the annotated genes and drugs, identifying interactions with 15 opioid-related drugs, including lofexidine and tizanidine, both previously used for the treatment of OUD-related symptoms. Conclusion: Our findings suggest a role of mCpHs for OUD in cortical neurons and reveal important biological pathways and drug targets associated with the disorder.
KW - epigenetic
KW - methylation
KW - non-CpG site
KW - opioid
KW - orbitofrontal cortex
KW - postmortem human brain
UR - http://www.scopus.com/inward/record.url?scp=85147313915&partnerID=8YFLogxK
U2 - 10.3389/fpsyt.2022.1078894
DO - 10.3389/fpsyt.2022.1078894
M3 - Article
AN - SCOPUS:85147313915
SN - 1664-0640
VL - 13
JO - Frontiers in Psychiatry
JF - Frontiers in Psychiatry
M1 - 1078894
ER -